1. Home
  2. LSTA vs GRML Comparison

LSTA vs GRML Comparison

Compare LSTA & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$1.54

Market Cap

28.9M

Sector

Health Care

ML Signal

HOLD

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$3.11

Market Cap

29.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LSTA
GRML
Founded
1980
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.9M
29.2M
IPO Year
2000
2022

Fundamental Metrics

Financial Performance
Metric
LSTA
GRML
Price
$1.54
$3.11
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
551.1K
5.5M
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
20.42
31.25
EPS
N/A
N/A
Revenue
$35,283,868.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
56.90
N/A
52 Week Low
$0.99
$0.16
52 Week High
$5.07
$11.66

Technical Indicators

Market Signals
Indicator
LSTA
GRML
Relative Strength Index (RSI) 46.30 50.45
Support Level $1.23 $0.20
Resistance Level $2.11 $11.66
Average True Range (ATR) 0.23 0.70
MACD 0.04 -0.30
Stochastic Oscillator 42.61 3.11

Price Performance

Historical Comparison
LSTA
GRML

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: